EBC - ON DEMAND
Regular DES versus Paclitaxel Sirolimus dedicated stent. POLBOS randomized trials
European Bifurcation Club 2013, EBC 2013 – London, UK
NEWS SESSION
Regular DES versus Paclitaxel Sirolimus dedicated stent. POLBOS randomized trials
Author: Robert Gil, MD, PhD, Central Clinical Hospital of the Ministry of Internal Affairs, Warsaw, Poland
POLBOS STUDY
- Primary end-point
- MACE event rates at 12 months
- Secondary end-points
- Device performance
- implantation failure rates
- Periprocedural safety
- rate of periprocedural SB compromise (SB closure rates, elev. CK-MB)
- Angiographic (after 9 months):
- Late Lumen Loss (LL)
- Percent Diameter Stenosis (%DS)
- Binary restenosis rate
CONCLUSION
- POLBOS analysis has shown that dedicated paclitaxel eluting bifurcation stent provides satisfactory results which seem to demonstrate equivalence in end points (death, MI, strokes, TLR) comparing to paclitaxel and inferiority to –olimus eluting stents and therefore POLBOS II Study was designed.
- POLBOSS II Study data are pending.